I cannot stress enough on Linda’s recent deal with Huawei’s purchase of part of the company’s land and nwbo’s right to lease back the land for 40 years:

It removes the most perplexing issue of constant financial stresses, imminent bankruptcy chatter, and it thus assures investors while stirring up the wolves’ holes – if the wolfpack were not disarranged yet it will be soon, and if big pharmaceutical companies are still waiting for the demise of the company or a convenient time to grab yet another trophy cheaply, they will find out soon that time is long gone.

The financial resource of $47 million or so may not be a big deal for big Ps and even some individuals with billions in their disposals, it certainly is a big deal for a constantly struggling small biotech company which has endured all sorts of attacks and defamations from any angle imaginable.

In particular, with the positive data revealed from the two interim blinded data sets which suggest DCVax-L is superior to any existing treatments, including Optune in treating one of the deadliest cancers GBM, in terms of not only efficacy but more importantly its pristine safety profile and its ease of use.

Due to its specific MOA, the beauty of DCVax will not be only limited in treating GBM, but it can be potentially used to treat almost all other forms and types of solid cancers, and in combinations with other immunotherapeutic treatments such as ICI, etc. it can potentially increase the efficacy of these already commercially successful treatments significantly.

The intrigue and peculiarity surrounding the deal may also have cracked open the dam of not only all sorts of speculations but more importantly all sorts of possibilities, not only from investors but potential competitors as well.

So it will be interesting to see what truly awaits us investors ahead, which I can almost feel it, and it will be all good.

It’s almost like a new world and an old world is colliding again. Will it be a bidding war coming soon or it is one already?

The strategy is to delay share price appreciation after Linda secured 47 million land deal. The time has come to gradually reflect the true value of the stock.

For me I only need to ask the two, and essentially only one question below:

Hi Linda, with all the data we have had, including the two interim blinded data sets, have you or your deputy Les ever tried to recruit or contact some significant influential Wall Street investment funds or banks so that they may initiate a significant position in the company after their own DDs? If yes, what's the results?

If some Wall Street funds were interested in the company and wanted to replace you as CEO with any means such as buying out the float and/or making derivative transactions behind the scene so that they can become the majority shareholders of the company, will you be willing to yield or will you instead fight for your continued control of the company but in an open and transparent way?

I will very much appreciate if anyone who attends the ASM asks the above questions.

All those people who scream no transparency should be stop. In a sense yes I agree with you guys that Linda should release any positive piece of news like a normal company, but I applaud her for not having released any insignificant news which can not move the share price but only those required by SEC.

As anyone has understood by now that we have been attacked unprecedentedly, and only news such like topline would move the market.

That blesses those who have conducted their own DD and come to the conclusion that the trial must be a success so that their seemingly-go-now-way stock will move when time comes.

As we know, in the field of GBM, not much progresses have been made over the years, and SOC has stuck in the range between one and two years for overall survival for the GBM patients. So the data released from the previous blinded and blended interim have shown strong probability for the trial success.

Nonetheless, some may still wonder if there are no differences between various comparable groups such as the early and late vaccined patients in OS, etc., then regardless of how beautiful the blinded and blended data may be, the risk still exists.

Well, in addition to the above, we also have had the very beautiful data of those thirty something of patients enrolled after the halt who seem to have received DCVax-L vaccine only, and these patients have all gone through more than 38 months after surgeries.

If we know they perform better than the blended, then bravo ladies and gentlemen, we have a winning ticket. So really don't blame we don't have enough news!

On the other hand, if the market is all smart most of the time, we would not have had this opportunity.

I bought 9k more today.

I am not a fan of Linda Powers. If you wonder why please go back one post of mine to see how come, but as I also said repeatedly she deserve some applauses for taking the trial pass 36-month mark for every patients in the trial, and her efforts of not further diluting the already-diluted-to-death stock, and her recent deal with Huawai.

China is the largest trading partner of the US, and many, many other countries as well. I guess many posters in this board have never ever visited China, let alone recently, that may partly contribute to sort of xenophobia or sinophobia as if the Boeing, the Big Three Autos, and the countless other companies and entities had never been doing business with the Chinese.

So Linda deserves a specific applaud for her looking beyond the obsolete and ignorant “old stock” mentality in pushing forward trying to materialize and realize the full potentials of DCVax platform.

It is also important to watch her closely and convey to her our true feeling on how all things of nwbo have been done, particularly because lawyers by trade are generally so happy walking in borderlines. Because she will be elected anyway, she must be warned so that if things finally pan out as good as expected she can finally throw off her self-interest shackles.

Nonetheless, I fully agree with notbrad post below in quotation marks:

“
I, like many of you, am growing impatient and have been pondering the timing of the unblind. I've come to the realization that pressuring LP to unblind, against her best judgement when she has the most information and the counsel of the SAB (and no doubt LL's too), could potentially lead to the wipeout of my investment. I don't want her to take that chance. If waiting a few/several months if it increases the odds of my investment paying off, then by all means I'm for it. I can wait till June if that's what it takes so that I'm not left with a big empty egg in my brokerage account.
By the way, what is the significance of this 46 months that has been mentioned a few times by some posters lately?
”
Particularly, now the government has been shut down and if Linda is waiting or thinks it is better waiting for something definite from the government (FDA, or even SEC), yes by all means I can wait for a few more months for the release of topline data, even though I believe they have been busy scrubbing, and even maybe have locked the data.

For me, a few more months makes no difference as I have decided to hang on with this stock for years to come if there is no buyout. So really it is critically important to give Linda all means and time at this stage to secure the first victory with regulatory bodies with our DCVax platform if it is necessary!

I expect her coming presentation on 23 Jan will surprise!

On the Management:

As I have said many times in the past, the reason for the ultra low share price is because we have not had a major long fund which has taken a significant role after Neil fiasco, and the reason is Linda Powers has scared off any of those kind of funds, and the reason again is that she has shown the only thing she cares is the control of the company, which in general is okay, but the problem in her case is that she doesn’t want to do so in a natural way, ie, let the market to decide how that kind of control will be.

It is suspected she had seemed to be reluctant to see price appreciated fearing that she might have to put substantial financial resources in order to maintain her control; even today she is the only person with the so-called preferred stake which can be converted at convenient price and time to maintain her control in case some unexpected events take place –- the impression still is that she will do her utmost efforts to control the company at the cost of everybody who is the owner of this company, let alone the vast numbers of retail investors.

So she was really the person who was solely responsibility for the misery and ultralow price that all share holders had to bear in the past.

Hopefully the future will be different as we are waiting for the topline data from the trial to be announced in the near future and the company just secured substantial financial resources which should be enough at least for a year.

So financially she has no excuse to once again resort to her dirty suspected tricks if necessary to maintain the her control of the company at any means, fearing one or few substantial funds or parties will taken over the company by buying out the float either gradually or suddenly via open market in combination with other derivative ways. Nonetheless, she must be welcome to such moves if there are any, and if she still wants to maintain the control of the company, she must compete in the open and free market!

Until she sends off that signal, the journey will still be treacherous. As we can only judge anybody by what he or she has done, but not what he or she will do. We must send her a signal of our unsatisfaction and disapproval of her past performance. ASM is one of such occasions we can do so. So I am going to vote no to all proposals except company’s auditor.

For those who lack experience, let me assure you she will 100% survive as CEO after ASM because she will still be the one who has the most votes even without any yet votes from retail investors. Besides she has not had any competitor for her job, but it is important to send a signal of our unsatisfaction and disapproval of her past performance!

At this point of time, nobody can kill this company and this company will rise into stardom in cancer treatment arena if the data are as good as we expected, which I think they will be.

At this inflection point and beyond, I sincerely call upon Linda, you get to change in your behavior and don’t stand in the way for DCVax platform to achieve its full potentials ASAP!

In God’s name, what I said above are my true belief and I have been a substantial investor of this company since German HE news and my share counts have only significantly increased over the years, and I may continually purchase shares at the time I deem appropriate, because I believe it is a right thing to do and it is a sane investment even after considering the so-far-not-very-positive factor of Linda Powers.

Anyone should do what is important in your life and let this stock plays out itself, because it will regardless whether how many posts bulls and bears continues to feed in this board.

All matters have been repeatedly disputed/discussed in all angles scientific, technical or financial.

All hinge on whether there will be differences between various comparable groups, which can only be known after top line and beyond. Fortunately, Linda has no reason or has run out of any reasons to not release topline within a very reasonable short period of time: from now to within two months or three.

For a stock which will be easily manipulated up or down 15% with measly 1 million shares of volume a day -- a quarter of million dollar of which maybe only a quarter of that quarter million is real with the rest go from left to right hand or vice versa, really there is no reason to worry about these measly trading, for both bears and bulls.

Whether Linda's upcoming presentation is once again a carrot or not really doesn't make any sense as we are close to data announcement.

If I have to guess to make a post more interesting, Linda's presentation must have something in mind; if only a carrot dangling like in the past, she will be shamed in ASM shortly after her presentation. And it seems her presentation is added recently and even today her name is missing from speaker list. Could that be a discussing about topline data, who knows?

Again nothing is important as we are siting at a laughable one tenths of a billion market cap waiting for perhaps the most important news in coming years regarding cancer treatment in human history.

Last warning for fellow longs, if you don't want to push out of this potential life-story significant investment, don't be fooled by anyone including yourselves, but please do make adjustments as to what you can lose in case unthinkable happens.

For me, I will go bolder to increase my position.

As for ASM, I will vote no to all, as the whole management will not deserve anything they have asked for for years. Until the topline data, I am pro buying stock and against the management (she will have a pass in anyway, so doesn't really matter how you vote).

As said before, anything will change immediately if a big long is coming onboard. I mean anything!

Answer to your Q re Doc's statement: his imagination or at best his educated guess, ie, those are not facts.

Now let me say something not related to your post or his.

Now that the treasure box has been cracked open by the external force of Huawei, which still needs to be confirmed in more specifics, the financial side of nwbo has changed from constant night to day.

The reported interim results are very positive suggesting success of the trial, which still needs to be confirmed as well as whether there are differences w/o statistic significance between various indicators/endpoints: PFS, mOS, and early and late vaccined patient groups in terms of OS -- mOS, milestone two, three, four and five years of survival, etc. If you believe the standard care for GBM has not improved much over the years, it is reasonable to believe there will be significant differences discussed above.

With torrent nagging financial issue behind us, it is just a technical issue as to when the share price will be reflect the new reality -- move to where it should be -- normalization process, and I would guess it should be around $0.5 ~ $1 range.

With topline data basically anytime from now on to within months, with positive revelation, the market cap should move up to between $3 ~ 10 billion dependent on which existing comparable company you compare, or what parameters you use to evaluate the company with various valuation methods, which are equivalent to a share price from about $3 to $10.

That is just for DCVax-L for GBM.

Short investment thesis:

The price in the range of around $0.2 will be the bottom, even with the worst scenario without FDA's nod for approval based on the current trial results -- the two interim blinded results have indicated the worst case would be ambiguity or mixed bag of efficacy, with its pristine safety profile DCVax-L will be destined for eventual approval by all authorities, even with a supplementary trial.

To be clear I believe the above presented is just for the argument purpose to see what could be the unimagined worse case, despite my belief that DCVax-L will be approved based on the current trial (I am 80% sure).

With a market cap of currently around $100 ~ 150 million at about $0.21 a share, and the worst case presented above, I don't think share price should go down any further, although it is likely to see big swings of a few cents in either way, but eventually it will come to reality--the platform is still promising, and with an improved design it will be readily a success (I don't know why I once again come to this worse case?)

The biggest issue at this point regarding share price is that we don't have a big caliber long fund in support -- the Bigger fund is just vulture in nature and just in this time goes long; with a true and substantial long fund's support, the open market will be supported, and the current MMs's cheap game will be over. In this sense, any fund who can commit itself in tens or several tens of million share purchase in the open market will be in my view such a big caliber long fund.

Without any concern of BK in at least the whole 2019, and with topline data expected to be announced within months, there will be much more positives than negatives (if there are any. Linda this and Linda that is obsolete; face it, she will not go anywhere. the only way she will be gone is she presides a buyout from a big P, or even Huawai!)

As we enter a bear market, health care stocks will shine; the self-destructive Donald would surrender to a face-saving deal with the Chinese.

It is just that a big caliber long fund is still on its way here as Mr. Warren lost billions of his investors' money in a single stock (APPL). I know nothing about these pathetic WS gurus, but would prefer to put my 80% worth in a tiny biotech company because it will outperform all stocks currently existing in a few months!

Things may change very quickly and if not, the topline data will change them once for all. That is only a wait of months for the worst.

If I have extra dollars I will be adding though I already have enough: 80% of my portfolio is in nwbo.

What I have heard and observed is that more investors are coming onboard and they are smart:

As long as there are no significant dilution I am happy which I have said before and that's the only problem I have had with the management.

Now that since there will be no dilution or no need for dilution before topline data, those on the sideline before and those who come to know this company recently will take initial positions in anticipating of topline data anytime from now to next few months based on strong scientific indication, including the two interim blinded data showers of 2017 and 2018.

The problem with the share price after Woodford is that there is no support (at least by a big fund) and the Bigger fund is just a peanut which is long but vulture in nature in my dictionary. So it really is that the share price has had not support except a price where mass retail investors would buy.

It is the best interest for MMs to maintain a low price for their profits or low cost maintenance of the market.

All these may change, because it not now there will be never for those funds which have so far been hesitant to get in big, or they can have fun and make profit at much higher price, like in dollar; I guess with two interim blinded data sets, it is most likely some funds may come to believe the strong possibility of success of the trial.

On the other hand, Linda has been successful in executing her masterplan recently which I believe is because of the strong data we have known today and the very fact that the trial is concluding with topline in horizon; the recent Huawei deal is an example, and I believe it is just a harbinger for more to come.

In some common license deal, the potential licensee will require to buy in the open market for a substantial amount, such as 10%, in addition to upfront money, etc.

All in all, there will be a variety of possibilities for substantial share appreciation, but I see nothing for share price in opposite direction (a temporary share manipulation of a few cents with low volumes is of course a possibility, but that is not my concern or a trend in my dictionary)

I would buy as much and many as possible if funds are available!

A random thought about the recent Huawei deal and the ignorance some poster shown:

Shenzhen City where Huawei headquarters locates was a village roughly 40 years ago before China implemented its opening up and reform policy. Today it is perhaps the most dynamic and vibrant city in China, more than the traditional most active and today-still-is Shanghai. Shanshen with its population of approximately 15 million is now well integrated to Hongkong, even Zhuhai by any modern transportation existing in the human's world.

Can anyone think about this that 40 years ago New York City, or Chicago or Los Angeles were not existing, just was Shenzhen city, let alone Huawai?!

So the mentality is quite different in what we are thinking and what the Chinese are thinking.

For us, nwbo is a struggling small-cap developing biotech company, but for Chinese nwbo is quite well established, more than long ten years in pivotal stage cancer vaccine trial (OMG! ten years!). I have no doubt they can and will pay very dicey expensive price for a partner deal or even an ultimate buyout deal if no strong enough resistance due to sinophobia or today's Donald Trump Syndrome.

It's exactly because China's biotech or health care industry is relatively lagging that Chinese government has encouraged its development more than others, this and that lies the opportunity for major M&A!

Out of the box, anything is possible and it's a pity we had the exactly Chinese thinking about 100 years ago, and today what we have left is only that WE ARE THE BEST IN THE WORLD, and yes the fact is yes we still are. Kind like the stock market, when it peaks, watch out! Then, it comes Donald, OMG!

All in all, never think never! Perhaps the best moving forward for the company is to give Huawei a license deal for anything outside of the US, and let a f**k*g big Pharm take the crown jewel US market?

About the Reason for the partial hold for new patient screening and the subsequent company’s actions, behaviors:

It is most likely the company had its first interim analysis in summer 2015, and there is thereafter no further interim analysis which has been conducted.

Results: It failed its primary endpoint PFS, due to yet to confirmed but strongly suggested pseudo-progression at the time, but today there are strong evidence and data indicating it is indeed pseudo-progression that wreaked the havoc. Because of that, DMC recommended the company to start a new trial with new primary endpoint, but the company refused, out of the consideration that “it seems every patient lived and is living longer.” DMC disbanded and the trail continues per “the protocol.”

FDA suggested to the company to stop new patient screening while the company raced with time to prepare and submit “certain information from the trial” for regulatory review in an effort to persuade the FDA to hold on and let the company to complete its enrolment, but FDA wanted the company to sort the mess out first.

The negotiation between the company and FDA then continues over a variety of issues, which may include how to adjudicate PFA events, change primary endpoint, modify the protocol, use milestone 3 years, 4 years and 5 years of overall survival as the primary endpoint, etc. Over the long process, some issues may become non issues, but new issues may emerge, etc, all seems pioneer in nature.

Hoping to have a definite nod from FDA and matured enough data, the trial marches on and on and on, obviously passing the previous planned PFS, mOS analyses, the said moving forward to lock the data, etc.

Today, with strong data known although on blinded base, including 2017 and 2018 interim blinded data in a positively trending fashion, the company is confident enough to finally decided to move forward to completing the trial (in all my faith, I strongly believe the company has started completing the trial without any hesitation! And the topline data will be out within the next few months if not a couple of months before next March)

News about FDA’s nod is still a possibility before data lock, but with Donald plays the US and the world like playing his favorite toy, and now the government is partially shut down, including FDA, the chance of a breakthrough with FDA before data lock becomes increasingly impossible.

I believe as long as the company finalizes or prepares its SAP, the trial data will be locked and soon after the topline data will be released. (except for topline data, the company may choose to not announce all other processes, such as data lock)

At end of the day, it’s the patients living longer or the undeniable efficacy that matter for the patients, us investors and FDA approval!

To conclude, please also not forget the demonstrated pristine safety profile of DCVax-L, which in today’s world and to a substantial degree is much more important than some efficacy which will warrant approval, but judged by today’s data known the efficacy of DCVax-L is lots of more than a blessing and is a substantial advancement in how humans treat GBM.

Due to its unique MOA, the implications of DCVax to play an important role in future cancer treatment in a whole are huge.
Merry Christmas and a very happy new year (I used low cases for the obviously reason)!

Even a blind elephant can see this deal with Huawai is golden, and a huge win for nwbo and its shareholders.

Before this deal: we are nobody, struggling quarters after quarters for survive for years. We are an abandoned orphan, who nobody wants to adopt, not by big Ps, even not by our government. In one word: we are cursed, and beaten to the ground by naked shorts wolfpack.

We have a so immense a platform (DCVax) that it has the potential for treating or helping to cure more than 90% of solid cancers, which is perhaps a single most fatal threat to the existing big Ps for potentially losing of their lucrative chemotherapy and a big chunks of ICI and cart-t business. The established big Ps are “burdened” with their legendary and existing business, if possible, no one wants to get into DCVax business since it will be a fatal threat to their existing business model.

Thereby, it is easy to understand why we are heavily shorted with unlimited faked shares; why FDA seems to have ignored us for so long even though we are just some short miles away from FDA headquarters; and you name it.

Politics aside, the Chinese has the view of big pictures. Its government encourages its people and its corporations to take risks, and of course short-cut, to move forward, to catch up, and to lead. Besides cutting age IT, AI, etc., one field Chinese government is encouraging the most is biotech. It will be the next big thing in China although it is still at its infancy. That’s why the coming of Huawai in doing business with nwbo because our platform Dcvax is a perfect match for any ambitious big Chinese corporation to get into the field and move forward in a lighting speed. And they have the resources to do so.

Now with this as a wakening call, we will never be ignored. Those big Ps who are relatively less burdened with chemotherapy, ICI and cart-t may finally realize if not now there will be never a chance to get onboard and lead again; For the US government particularly FDA, the future revelation is definitely not pretty if it continually ignores. To deny any future buyout deal with Huawai will be baseless since we are deemed a “garbage” by FDA and big Ps, and how can you say a deal of a “garbage” will be a national threat which ought to be protected?

Anyhow, I don’t see this deal is nothing but good, and its implications will be unfolding positively. For the advancement of mankind, I don’t care where DCVax will be used commercially first. Particularly if the US has declined its first right, let others to take it.

If I were a short, I definitely know what I should do unless the short is brain dead, and that is none of my business.

Now the purchaser has been known and it is a fierce Chinese telecom & smartphone company selling the most gear for today's high speed communications and more phone sets than Apple around the world.

It is the same company whose CFO Meng Wanzhou was arrested in Canada at the request of the US early Dec and is now out on bail... fascinating story still unfolding... due to Donald Trump's trade war with China...

Huawei, a private company with huge financial resources, which has invested more research funding than most western companies, one of the reason for its spectacular ascendance, thus at ire of Donald...because it is pausing to dominate new generation of communications -- 5G, etc

Politics aside, the company seems not to use the land it just purchased for making new generation of gears or fancy smartphones, or expanding its UK research base into the newly purchased land, instead it seems to allow NWBO to do all the necessary work for commercial use in the future, 20+20 years at least.

One implication is it may want to diversify its business and get into biotech and this is just a first step.

So it seems money may be no longer a problem because I don't think this land purchase is the first and last from Huawai or other biotech companies from China due to the publicity brought about by this deal to potential Chinese companies.

Besides, with the money in hand, Linda's hand has strengthened and she can make deals upon deals with other companies, toward eventual buyout by a multinational big P.

Without even a bit of worry about the demise of the company, anyone including wolfpack will eventually come to realization:

NWBO's success is an eventuality and unstoppable!

Linda ought be given maximal flexibiliy possible in terms of when exactly the trial will be locked and topline data be published.

The reason is quite simple: the only thing wolfpack has not been paniic yet is they know there is no imminent danger of topline data or its equivelent like substantial interests from long hedgfunds, or substantial lisence deals, buyout, or the like, as there now will be no concern whatever of the demise of the company for at least one or two years due to the recent secured funding from the sale of property.

Unless there is a mole in FDA who is feeding the wolfpack of inside information, in my opinion the only hope for the wolfpack to not be panic is a clear guideline from Linda.

If you are longs who do not depend on flipping shares to average down and have hold the opinion that no matter what the trial will be a success, and the the treatment will be approved, I don't think it will be hard to not give her all the resorts she can have.

Because of wolfpack, we have been suffering too much; the patients have been suffering too much; and the general investment community have been deprived of true and correct information about this company and its disruptive and promising immunotherapeutic platform. So it's time to give Linda the trust and means so as to uproot the wolfpack once for all, because it is the best interest of all stackholders and patients.

I believe we are near the truth\news, and I have no problem to wait a few more months if we have to.

The way LP/LG put out a news piece in ambiguity regarding unblind days obviously has its reasons -- I am holding why at this time!

The property transaction suggests the deal is signed with a big P for license right of only L, and the way or term it is at this time is provisional -- the big P would only take a friendly risk which is all written in the terms suggestively.

Until a definite signal takes shape, certain, the P would emerge and the deal would be finalized -- either a license deal or a buyout. All depend on

a sudden truth -- a yielding of authorities to fact and truth.

Until that day, we will continually see ambiguity, or total silence.

I prefer the latter, but doubt it (Linda has failed me by behaving exactly like a normal CEO, which most in this board love to have, but not me).

Have made my minded, the only thing I can do is buy as long as I have funds!

Buy

[Referred to Basin Street Blues's post] regarding naked short practice here of nwbo, your opinions and analyses are pure nonsense!

Even a kid can infer the naked shorts are alive and well even after nwbo delisted from NASDAQ to OTC. Linda's previous toxic financing/dilutions just exacerbate the situation.

No time to detail my opinion, interested check back my previous posts regarding naked short activities attacking nwbo.

Very interesting, people even the ones making living by trading are blind, and brain dead regarding this issue, and it is appalling!

Regardless, the share price will appreciate reflecting on the fact we have known today. Wolfpack just hopes we don's have a momentum, and that's why they pour cold water (naked short selling) at any good news in a very patterned sneaky way.

Time to go and buy (not misspelling)

So the company has further matured data which is again encouragingly positive in nature

-- the company ready to move to close the trail, not multiple stages and multiple months for each stage instead it is a process of "months"

-- the UK property sale is once again a slap on faces of naysayers/wolfpack who have said the property is almost useless or a bad initial purchase

All in all, it seems an ultimate buyout plan is in play. Good for investors and good for patient!

It it feasible and/or more powerful to make DCVax-L vaccine from DCs extracted and isolated from healthy bloods that can be readily obtained from healthy donors or from general blood bank, cultivated and mixed with patient's tumor mass, ie the same way with only the difference being the source of bloods for DC.

So the very invasive blood procedure can be eliminated, and the vaccines can even be made for patients with much worsen conditions which was previously impassible

Did the last dozens of patients use such vaccines?

Ignorance or imagination is boundless?

Nobody posting it's gonna be a very good day!

I am talking about nwbo of course. Thanks for saving lots of time!

Hi maverick_1,

Good luck to your new endeavour. Remember to come back to congratulate on us successful nwbo longs when topline data are released or a very substantial financial deal is made public, either a buyout or something very substantial.

Hi md1225,

It's reasonable to diversify considering you had held close to two million shares. Good luck to your new endeavour too.

I had continually added more shares. Now is more right time to add after all the new developments including the refreshed interim data, and those sited by others.

Only thing sucks is Linda's evergreen greediness. I am proud I didn't vote for her the last time, and I will find ways to combat her excessive greediness, meaning retail investors have not received due, or even a fraction of the respect compared to her greediness.

Be prepared to buy more at every pull back.

The dynamic has changed for the company Ladies and Gentlemen, despite the “evergreen’ greediness of Harvard educated chick Linda Power.

In regard to the incremental increase of option pool disclosed in an 8k Friday, nothing you can do with it; it’s perfectly legal; and it is a demonstration of chick’s dexterity. Nonetheless, I do believe bad karma will get the chick in life and it’s just a matter of time, if she has not taken care of her vast numbers of retail investors in a fair way.

Nonetheless, the dynamic has changed thanks to the revealed beautiful continually improved blinded interim data sets as of 2017 and 2018; to chick’s series of moves, including forced conversion, the unbearable multiple months of long dying quietness, etc,

As a result, it may have borne the fruits. For example, the late stage multiple parallel negotiations for substantial alternative potential financing disclosed in a recent SEC filing.

In addition, the chick has recently declared the time is now to have the data analyzed following about-to-initiate or already-on-going four multi-month stages, which in any way and logic, must be four parallel processes and can be conducted simultaneously. For most company, it is a mere within three or four month task. Again the chick has demonstrated her dexterity to reward her employees with a cheap option exercise price of $0.25, instead of $1 if she had had a normal news release of the same content, while preventing any legal liabilities in case the chick’s promise fails to deliver, and if things pan out beautifully later, she will be complimented for underpromise and overdelivery.

Regardless, the dynamic has changed. Something and a lot of things are definitely coming into fruition in the horizon, in both finance terms and promising topline trial results.

In life, we have learnt we have to swallowed something because simply we have no choice; the chick has a bitter deed for us retail investors to swallow, but the open question is does she also have a much sweeter, much more grandiose fruit for all us to share.

The answer is a resounding yes so it’s better add more when the price languishes or simply sit back and enjoy the otherwise mostly positive and rewarding journal.

Yes, the dynamic has changed despite Linda being a sucking chick, but don't complain the chick has not given you a hint for what is coming.

DYNAMIC HAS CHANGED! Quality food takes time to digest. Shorts are toast!

First of all, today's data point of 3-year OS for blended population of about 28.2% is once again a testimony that DCVax-L works, and works beautifully, and the trend of an increase over 2017 3-year blended OS of about 25.4% is expected if the vaccine is working.

Since the data was taken as of the spring, the data will definitely increase when data was locked which I suspect it happened in August.

As long as manufacturing improvement is concerned, the few posters who have talked this to exhaustion seem to have no basic grasp on clinical trial requirement, particularly the registration phase III trial.

So all those manufacturing speculations are just of ill-knowledge. Of course the manufacturing process has been improved, but the suggestion of adding those improvement into the existing trial repeatedly is just nuts despite good intention.

Today's data point is huge coupled with anticipated "substantial alternative potential financing" deal or deals in the near future, which is at least one more nail down on the wolfpack coffin.

This time Linda seems to finally have something in a row.

Simply put IMHO that Linda has blatantly filed to SEC the reason for the delay of Q filing so those parallel discussions with different third parties for substantial potential (this is the only word I don't like) financing are real and should be indeed late stage. Now less than 24 hours later, the Q is filed to SEC, which can only mean that the process, i.e., discussions are continuing and Linda would not expect the deal or deals can be concluded in five calendar days, or she simply wants to give an impression that she is not in a rash to close a deal or deals.

On the other hand, if the deal or deals are closed before five calendar days and the Q is filed then that or those substantial financing deal or deals will be buried somewhere in the Q, such as in a footnote disclosing that or those material news, which is not desirable in any way.

So a better way to do it is to close those deals and file to SEC in a separate filings such as K filing, and that will make the news more substantial and significant.

SO I expect one or several 8-k form filing to report those deals or deal in the near future, with Monday the earliest because one deal can be closed technically anytime after the Q filing, which is this evening.

If we see trading halt for those kinds of filing, that would be really substantial.

Has Linda had other news in her disposal besides the above?

Two things: [edit: not intended to reply to scotty3371, but for independent post]

1. The White Paper

It confirms MOA of DCVax-L supported by clinical evidence, for example the favorable delta compared to SOC, Novocure, etc. With a clear MOA approved, the success of underlying trials is almost certain.

The beauty is not just that for DCVax-L, but it is shown that by tweaking or modifying and/or combination with other agents, DCVax can extend benefits ten to hundred of times potent, which indicates much larger potential in the future.

So if DCVax-L is worthy of 50 billion cap, 5-10 multification of that is reachable for DCVax platform including D, which will be a huge market potential

2. Trading as usual indicating the control of wolfpack. For instance

Bid
CDEL 0.2099 22,515 09:58
CSTI 0.202 100,000 09:42

Ask
OTCX 0.21 5,000 09:30
CSTI 0.21 100,000 09:56

The question is WTH is it important or of any sense if one wants to buy 22,515 shares asking 0.2099 when the ask is only $0.0001 higher than your asking price with tons of available shares.

Without volume and continued enthusiasm or news, the wolfpack will still have your lunch.

you have it right. The best Linda Powers can and shall do is to talk to regulatory bodies, while ignoring all noises, either shareholders or not as much as possible.

As long as there is no leak, she will have no problem, and it seems there is no leak.

Thanks God, I like to buy more.

Oh, let it be, and let it be. This is an investment board, not a competition of who is right and wrong on what board.

Several characters in this board seem care that more than valuable information which can be used to make a better investment.

See, even a broken clock is right twice a day.

What's important is is this trial a final success so that it can extend patients life, and so that we investors can make money from it.

I believe it is, and we will and even more than just that judged by its MOA.

I saw you quoted the same in iVillage too. If you really want to get a full picture of what Dr. Linda thought about this issue at that time years ago, see below her email (courtesy of Sentiment).

"Question
Dear Dr. Liau: In your video last week (and also last year), your comments seemed quite positive about the patients living longer, but last week you also seemed to say that DCVax would not be able to get FDA approval. Is that what you really meant? How could that be the case if patients are living longer? Would love to have clarification on this issue

Thank you in advance for your time .
Xxxxxx xxxxxxxx


Dr. Liau's answer

Hi Xxxxxx,

Yes, the patients do seem to be living longer with DCVax; and no, I did not mean to say that DCVax would not get FDA approval. I was making the point that, whether or not the study fits a particular category endpoint, there should be a way to get approval if the data shows that the entire group of DCVax patients (in both arms) does better than concurrent/historical controls who have not gotten DCVax.

Hope this clarifies the issue.

Thanks,
LL

Linda M. Liau, M.D., Ph.D., M.B.A.
Professor & Vice Chair of Neurosurgery

Director, UCLA Brain Tumor Program

UCLA Department of Neurosurgery"

The beauty of this trial is that even LL has not expected the trial could be extended this long today when the last patient has almost been enrolled three years thanks to another Linda's stubbornness and determination, which may even provide ss differences between various groups such as the early and late treatment groups.

This will soon be an unprecedented data rich trial ever in history.

For the sake of your constant efforts you have made in this board countering anything positive regarding nwbo, I can only say this to you:

If you have a shredded bit of real time experience in small biotech investments, you would realize that for any and each dump, the holders of the shares to be dumped, i.e., the vulture funds who hold those vast numbers of nwbo warrants specifically, would have always hyped it and then come the dump.

Where is the hype you have seen in this stock besides this message board, man? They can hype this stock to much higher price via buying wiling and readily available journalists, bloggers, or people like you, etc., to hype the price with constant speculative news, rumors, buyout, merger, partnerships, night club hearsay or hearsay, and you name it, in any places and manner possible.

Then, the price would have rise, while innocent investors would have been doped buying in the hype, ...

That's the way and only way of a pump and dump, which has not happened with this stock, and it seems it will not happen. This is a big plus indication, along with forced conversion, no public financing but Linda's own money loan, of course the interim blinded data.

So it seems warrant holders have been unwilling to spend a penny to hype this stock they want to dump or already dumped, nor our dear leader CEO Linda Powers who is as quiet as dead!

So what on earth is going on and happening?

Well, I can tell you what has been happening recently: LP is super busy working on her master plans to bring DCVax-L to undeniable success, and she then will go after those who have committed criminal acts against this company and its share holders and suffering patients. She has no time to watch share price and has no interest to get distracted as data have been scrubbed, talking with regulatory authorities including FDA, etc. We are approaching the major inflection point which must be good, or super good.

For that, I bought 10k shares to add to my large position to conclude my once a day post.

It's particularly important to have someone called Les to have at least the face value of the report of the talk to talk about for fun while we are obviously in waiting, waiting and waiting for something of substance to happen, instead of talking or debating about some imagined trigger of event rate, or rate of event accumulation or the like

It's blinded. There may be signs for trending of the trial, but there is definitely no telling of the trial results, let alone statistical magnitude, ss or not.

Anybody reporting conservation with Les at this point is very much appreciated!

He is a pro nwbo now obviously by the paper he provided.

18 months v 23 months
inferior process/manufacturing
almost ad hoc preparation v decade of painstaking invention, trial and error, progressing, secret sauce
small data set/patient population
failed to or not intended to catch long-term survival

.......

unless the air is different in NY City and Los Angeles or London. And anyone can definitely list a long list of differences

At least I can

All point to a very successful DCVax-L trial results

Nothing new here, nothing.

The fact is that we don't know if L will be a definite success (we include Linda Power) until the last shred of information unlocked from unblinding. You may have reason to not believe many things Linda has promised or said, but you can trust her when she said the trial was still blinded. That's a redline nobody wants to pass if he or she wants to get the treatment approved by FDA.

The good news is the blinded interim result publication, which suggests L could be more than 80% success if the control behave the same or similar to all the precedent trials: below 20 months from surgery; coupled with 1/3 of population in the L trial who have performed very well, with no known reasons to explain but the efficacy of L, now that needle can move to 90%; if the trial indeed can capture the long tail, I am certain L will be 100% approved by FDA.

If she doesn't have the confidence, she would have diluted again and again in the past several months; Instead, the company is being run with loan;

If she doesn't have the confidence, she would have launch at least one if not several combination trials or standalone D trials for multiple indications.

She has given too many signs to you. No one should blame her for not communicate enough as long as you have ears, or to be exact brain.

She will surprise the market as observations testify once again not many investors deserve multibaggar, let alone 50 ~ 100 baggar.

There are always greener pastures for you folks. Fighting for one or two cents of price movement is pathetic if not pitiful.

Kam, honestly I really don't know. What I know is the approximate eventual market cap if the trial results are indisputably positive, which shall be at least 5 billion (about $5 per share), or about 3 billion ($3 per share) if the results are very positive but with some caveats, or about 1 billion ($1 per share) if the results are dubiously positive, or a few million if the results are indisputably negative.

In the meantime, too many factors could come into play, including how big will the squeeze be, are there any big name funds coming onboard, etc., let alone about future speculation: how about other indications if L is successful for GBM, how huge will be the market potential of D, etc.

Anyhow, one simple and mostly accurate estimation about future price is to compare nwbo with other similar companies in the similar sector.

Good luck to you and all nwbo long.

Odds, very odds that anyone would believe the company would meet NICE date of submitting evidence support unless he or she believed the company had secretly unblinded data some months ago.

Com'on, sell your shares and move to other normal companies where no high IQs or common senses are required.

BTW, evidence support means unblinded data which would testify evidence of efficacy.

If the company decided to unblind data when last patient has been 36 months after surgery, one would expect two to three months at least to have the topline data ready, which means October or November this year (August + 2 or 3 months), or 36 months after enrollment, one would expect topline data in and around Jan or Feb 2019 (November + 2 or 3 months).

There might be some secret activities going on behind the scene, which are likely but not probable.

If there is still no dilution from the company or as long as no dilution from the company although it can do it readily thanks to all your generous yes votes, some positive things must have been happening:

The forced conversion is one; second, no pump but silence; third, no other trial launch distraction; ... which all mean confidence, and anytime you are in doubt, go read the blinded publication again!

In this stage and after the company has been unfairly assaulted from any angles in anyways, Linda ought to operate in stealth continually.

A surprise is for the good of patients and long suffering long investors, Linda, you must remember that.

With half of my family nets have parked with this company resulted from endless hours of DD, I am confident enough to continually add shares until after topline data is announced.

BTW, what's our MC? Slightly over 100 million? Wow, please sell.

Sentiment, sorry to hear it and glad your husband is in recovering. You are one of a few persons in this board who are genuine, honest and smart who I like to read their posts.

You are brave and blessed too. My prayer for your and your husband.

I will ride this to the end with you and other longs. Like you when I am absent, nobody should interpret that as I have sold.

Take care!

Notice those inspicable characters in twitter who have all gone since yesterday. In the past they would come earlier than most so as to put a dent or impression of any company's sec filing or news with negative spin.

The one-eye funny looking "expert," the CFA/CFP guy, the guy pretending smart holding his chin, and the like have all gone not leaving even a word of comment on yesterday filing.

What a convenience, even Jerry in iv can only talk something like RS, and then admitted it is of a slim chance, unless the company wants to be relisted in NASDAQ (Gerry get real!)

Nothing has changed until it is changed.

Happy buying!

What it says:

Date Timestamp Price Volume Tick Direction Change
09/13/2018 09:31:47 0.185 5,555 -0.00
09/13/2018 09:30:04 0.186 7,400 0.01
09/13/2018 09:30:03 0.175 100 -0.01
09/13/2018 09:30:02 0.1855 2,500 0.00
09/13/2018 09:30:02 0.1855 100 0.00

It shows manipulation as always. I bought 18K yesterday completing transaction for hours, intended to see if really somebody wants to sell.

Conclusion: absolutely not. It's all walk down for unknown reasons.

So for me it is buy as much and many as you can afford!

Just done some travel around the world one month ago, and have since quietly waited, waited and waited -- still have tons of patience waiting for the fate of my investment, not a share sold and will not until the results.

BTW, came across an interesting article:

https://www.washingtonexaminer.com/linda-powers-a-keen-eye-for-the-right-opportunities

[part of it:]

Linda Powers: A keen eye for the right opportunities
by Katie Wilmeth
| August 11, 2006 12:00 AM

Print this article

Linda Powers knows an opportunity when she sees it.

The co-founder of Bethesda-based Toucan Capital has made a career of seizing new opportunities and making them work for her.

From an active career in corporate takeovers in the 1980s to a presidential appointment at the U.S. Commerce Department during the first Bush administration and, finally, to her current career investing in fledglingbiotechnology companies, Powers has had a front-row seat for some of the hottest developments in the business world over the last 20 years.
Seventeen Years Later: Remembering 9/11
Watch Full Screen to Skip Ads

Now, as one of the country’s most successful biotechnology-focused venture capitalists, she has been tapped to lead Maryland’s high-profile Stem Cell Research Commission. The commission is overseeing the distribution of a $15 million fund for Maryland-based firms focused on stem cell research.

The 50-year-old Potomac resident has jumped from one big opportunity to the next throughout her career — always seeming to leave at just the right time. She started her career at the law firm Latham & Watkins in New York, where she specialized in hostile corporate takeovers. Just as that hot trend was fizzling, Powers was appointed Deputy Assistant Secretary for Service Industries at the Commerce Department. After four years, she was hired at Enron, but left to launch her own venture capital firm in 1997 before the now-infamous scandal broke.

"I’ve been lucky with my timing," Powers said.

Powers, who co-founded Toucan Capital with her husband, Bob Hemphill, said the decision to start her own business was a natural step in her career trajectory. "I looked at the landscape and it seemed to me venture capital was an interesting area of opportunity."

Toucan’s first fund invested in a variety of companies, but its third fund, at $120 million, focuses solely on seed and early-stage bioscience companies — one of only a handful in the U.S. focused on start-ups.

"Biotech has the longest time frame and one of the biggest risks, but at the same time biotech provides great returns," she said.

Toucan currently has investments in 10 stem cell companies, including more than $60 million in Maryland-based firms.

As the new chairwoman of the 15-member commission, Powers will help define the state’s role in the hotly-debated stem cell researcharena.

"My favorite thing is working with scientists and first-time entrepreneurs and helping them take some kind of research results and turn it into a real product for the real world," she said. "I think success stories come in all shapes and sizes … but the key thing [for the Commission] is to do something that advances the science and/or advances the research to get something to the bedside."

[about her husband according to bloomberg:]

Mr. Robert F. Hemphill, Jr., also known as Bob serves as the President and Chief Executive Officer of AES Solar Power, LLC. Mr. Hemphill served as the Chief Executive Officer of AES Solar Energy, Ltd. He served as Acting President of Asia & Middle East and Executive Vice President of Strategic Initiatives at The AES Corporation. He has more than five years' experience in seed and early stage venture capital investing and over 20 years' experience in corporate operations, including two successful IPO’s and dozens of project and corporate financings, both domestic and international. He co-founded Toucan Capital Corp., and Toucan Capital Fund II, L.P. and served as its Managing Director from June 1996 to February 2004. He served as the Chief Executive Officer and President of Silver Ridge Power Inc. Previously, Mr. Hemphill was a Co-Founder at AES and a Senior Manager for over ten years. He served as an Executive Vice President of Global Development at AES Corporation since February 5, 2004, an Executive Vice President from 1982 to June 1996, a Director from June 1996 to February 5, 2004. He served as an Executive Vice President and Chief of Staff of The AES Corporation form February 2004 to march 2008. Mr. Hemphill served as the Chief Executive Officer and President of AES Transpower Pvt., Ltd, where he served as a Vice President of Project Development, from 1982 to 1984. He was an Executive Vice President of Business Development at AES Wind Generation LLC. From December 1993 to February 1, 1995, Mr. Hemphill served as the Chief Executive Officer and President of AES China Generating Co. Ltd, a Vice Chairman from February 1995 and a Director from December 1993. From 1984 to 1987, he was employed as a Senior Vice President at AES. Mr. Hemphill helped start AES Corp. in 1981 and in concert with his two partners, built it from a three person, one million dollar start-up to an international corporation with electric power generation and distribution and telecommunications activities in the United States, Europe, Latin America, Asia and Africa. Prior to Mr. Hemphill’s tenure at AES, he served as a Deputy Assistant Secretary of the United States Department of Energy, with responsibilities that included energy research and development planning and budgeting. Subsequently, Mr. Hemphill served as a Deputy Manager of Power at the Tennessee Valley Authority (TVA). He served as an Executive Vice President of Business Development at AES SeaWest, Inc. Mr. Hemphill has more than 25 years of experience in senior management positions in small and large corporations and government organizations. Mr. Hemphill serves as a Director of Reactive NanoTechnologies, Inc., Phoenix Motorcars, Inc., Selecterra.com, the Smithsonian Institution’s National Museum of American History, the Advisory Board of Optiglobe, the Advisory Board of Venturehouse, Trophogen Inc., and Chameleon Technologies. He served as a Director of Knova Software, Inc. (also known as ServiceWare Technologies Inc.) since June 2001. He served as Director of Altair Nanotechnologies, Inc. , from May 2007 to November 19, 2009. He served as a Director of Silver Ridge Power Inc. since July 12, 2012. Mr. Hemphill holds an M.B.A. from George Washington University with a specialization in Finance, an M.A. in Political Science from UCLA and a B.A. in Political Science from Yale University.

Unfortunately Linda is here to stay for a long haul, but she will be our friend and guarding as long as L and/or D has a decent chance of regulatory approval, because simply by having L and/D approved she will not only leave a mark in history but get really rich.

Yes she has demonstrated she is a selfish, greedy American capitalist, and even one who is short of a vision, contrary to what she put in her curriculum vitae.

And by making things worse, she and Les have consistently lied to investors and media, and have rarely done their jobs, fulled their fiduciary duties as leaders of a publicly traded company.

Those mentioned above are known to all, needless to repeat any further.

Nonetheless, at this junction point and after reading the recent published interim blended data, I feel time is now to lay trust, perhaps for the last time (for me actually is the first time, as I had been one of the persistent critics on Linda, particularly in her poor performance in securing funding and protecting share price) upon her:

We are faced with mounting difficulties from perhaps corrupted regulatory employees, the often and long-talked wolfpack, and even those funny individuals who trade for one or two pennies' swing with mood shifting like changes of baby diapers (thus the word funny), and those who persistently poke the company with any negativity, FUD imaginable and unimaginable regardless.

So I have placed my full trust upon Linda Powers and believe she will do the best for the company, thus us investors and herself, and for moving this innovative, safe and effective treatment into regulatory approval.

So I am willing to sacrifice and let her the free hand to operate. We have to defeat and totally cripple all forces negative and destructive against putting DCVax-L into regulatory approval.

My only hope of course is that she must not dilute us heavily and better borrow all the way to regulatory approval.

SHE KNOW MORE THAN ANY OF US ON WHAT ARE HAPPENING BEHIND THE SCENE AND CAN THEN MAKE THE BEST DECISION!